MPL-TL is the active ingredient of an approved topical preparation used for the temporary relief of muscular and joint pain. It has been shown in multiple clinical trials to act as a rapid and effective topical analgesic and anti-inflammatory agent, however more recent evidence points to an additional strong tissue reparation influence in acute and chronic muscular skeletal injuries.
MPL-TL is still in clinical trials but all evidence at this points to it being effective on three levels: it appears to act as an analgesic by blocking the specific nerve-receptors, it appears to inhibit side effects by acting as a scavenger of nitric oxide and it appears to promote regeneration of tissue and healing of ligaments and skin tissue by acting as inducible nitric oxide donator.
MPL-TL is different from aspirin and aspirin-like drugs in several ways. First, it is applied topically so it does not go into the stomach and flood the entire system with a drug. A significant property of MPL-TL is its localized effect and its lack of systemic actions. It is readily absorbed into the skin and diffuses rapidly into the immediate surrounding tissues. While its half-life is yet to be defined in vivo, there is little evidence to support any systemic drug interaction or remote effects.
No – unfortunately there is not yet anything that is effective for all types of pain. MPL-TL is effective to treat the type of pain that is generally treated with over-the-counter drugs and topical applications. MPL-TL is completely different from any of the topical compounds currently on the market. Other products mainly work by stimulating the circulation in the area of application and letting nature take its course. MPL-TL goes directly through the skin and blocks the nerve receptors that are causing the pain while promoting healing.
MPL-TL is part of a parent compound that has been extensively tested in humans for two decades and, to-date, no negative side effects have been discovered. Additional research is in process to determine exactly what it is that makes MPL-TL work so effectively and, of course, all efforts will be made to explore any further potential side effects. But with 20+ years of positive results, we are confident that MPL-TL is safe, effective and free of side-effects.
MPL-TL was created by the MPL medical team nearly 2 decades ago, at a time when proteomics and peptide therapeutics were at an early stage of development. The products that resulted were possibly mis-directed, however clinical trials showed that they delivered real and quantifiable benefits in a safe and side-effect free manner. MPL-TL has now moved on and is emerging as an important new active ingredient that delivers needed benefits across a range of common and debilitating disorders and injuries. It is manufactured in a manner that provides extraordinary precision in amino-acid sequencing and this alone may yet prove to be of immense value. MPL-TL's apparent side-effect-free status and low drug interaction profile may make it ideally suited to a range of conditions and disorders for which topical NSAIDs are contraindicated.
As MPL is a publicly traded company, all shares must be purchased through a Registered Broker Dealer. Your regular broker will be able to assist you with this purchase. The minimum number of shares you can purchase is determined by your individual brokerage firm. See Investor Information.
It is always wise to find a broker in your area you feel comfortable discussing your financial options with. If you don't have a Registered Broker Dealer in your area, you may be pleasantly surprised at how easy it is to establish one. While there are a great number of Registered Broker Dealers in the US and most likely one in your area, many people now elect to open an online account for convenience and simplicity. See Investor Information.
MPL's primary, general objectives are to:
• (in progress).
• Gain American regulatory and marketing approval
• Gain Australian and European regulatory approval
• Manufacture the new drug as a generic ingredient
MPL-TL will be developed primarily as a generic ingredient – a key active ingredient . In this form, it will be sold to external formulators for incorporation into thousands of new analgesic products for which there is a ready path to market and a willing market place – in the same way aspirin or ibuprofen are used as key active ingredients.
Molecular Pharmacology Limited, in cooperation with its scientific partner, announced in February 2005 that it had lodged completed patent specification in the USA and provisional specification in Australia for its propriety analgesic and anti-inflammatory compound, MPL-TL. The lodgement of a US Specification in Completion allows the company to seek examination in the USA earlier than would otherwise be the case. The patents seek to provide broad and early protection for the company's analgesic and anti-inflammatory intellectual property. The parallel lodgement in Australia provides the company with a single priority date in both the USA and PCT countries. The company has adopted this two-part patent strategy to support its international market potential.